<DOC>
	<DOCNO>NCT01842113</DOCNO>
	<brief_summary>The purpose study determine whether take Rifaximin ( Xifaxan ) conjunction use nutritional concept effective improve morbidity quality life cirrhotic patient suffer hepatic encephalopathy ( HE ) .</brief_summary>
	<brief_title>Quality Life Nutritional Improvements Cirrhotic Patients</brief_title>
	<detailed_description>Prevention portal hypertension complication forefront . In , end result improvement multitude morbidity mortality issue . The propose prospective trial compare patient similar demographic medical clinical setting utilize standard care therapy . Study subject randomly assign two treatment group . Group one receive Lactulose 30ml three time day SOC Rifaximin Placebo 550mg twice day nutritional supervision group two receive Rifaximin 550mg twice per day SOC Lactulose placebo 30ml three time per day nutritional supervision .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Male female gender Age 18 year old Liver cirrhosis define one following : Radiographically prove portal hypertension ( CT nodular appearance ) Liver biopsy cirrhosis Model End Stage Liver Disease ( MELD ) score &lt; 20 Willingness provide write informed consent , participate study requirement Sodium great 130 meq/L Conn Score &lt; 2 Active alcohol consumption Serum total bilirubin level &gt; 5 mg/dl History hepatocellular carcinoma ( HCC ) malignancies basal cell carcinoma skin Pregnant breastfeed woman Subject renal insufficiency require routine dialysis Poorly control diabetes define HgA1C &gt; 10 Narcotic/psychotropic usage stable dose antidepressant and/or methadone . Neurontin ( gabapentin ) Lyrica ( pregabalin ) permit subject stable dose least 2 month prior screen visit change dose expect throughout length trial Any follow diagnosis : HIV Evidence severe concomitant illness condition make unsuitable study opinion investigator ( ) Subject receive investigational drug within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>